<?xml version="1.0" encoding="UTF-8"?>
<p>Up to date it is possible to say that there is not an unique point of view and the controversial NSAIDs use in COVID-19 is still discussed (
 <xref rid="B8" ref-type="bibr">8</xref>), with recently a positive insight on ibuprofen in COVID-19 disease (
 <xref rid="B11" ref-type="bibr">11</xref>). As consequence there has been a drop in ibuprofen sales (as reported by Glaxo Smith Kline–GSK) in the second quarter of 2020 (
 <xref rid="B12" ref-type="bibr">12</xref>). Considering the burden that COVID-19 infection is imposing to the world population (both in the acute phase and in the so called “
 <italic>long COVID</italic>”) we thought important, therefore, to consider also other treatments that could expand our pharmaceutical armamentarium that could alleviate the symptoms of COVID-19 Infection.
</p>
